CTA
DNLI icon

Carillon Tower Advisers’s Denali Therapeutics DNLI Stock Holding History

Carillon Tower Advisers’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$17.6M Buy
+209,850
New +$12.7M 0.11% 268

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Carillon Tower Advisers's DNLI Position: Q4 2020 in Review

Carillon Tower Advisers opened a new position in Denali Therapeutics (DNLI) in Q4 2020: 209,850 shares worth $17.6M. The stake represents 0.11% of the portfolio and ranks #268 among its holdings.

205 funds tracked by Wall St. Rank hold DNLI as of Q4 2020.

  • Carillon Tower Advisers held 209,850 shares of Denali Therapeutics worth $17.6M as of Q4 2020.
  • Denali Therapeutics was a new Carillon Tower Advisers position in Q4 2020.
  • Denali Therapeutics made up 0.11% of Carillon Tower Advisers's portfolio in Q4 2020, its #268 holding.
  • 205 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.